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Objectives: Dental-biomaterials loaded with drugs are a promising strategy for local infection
treatment. In this context, some studies suggest the incorporation of chlorhexidine (CHX),
as  an antifungal drug, in acrylic reline resins for the treatment of Candida albicans associated
dental infections. The purpose of this study was to evaluate the release of CHX from one
acrylic reline resin, Kooliner (K). Furthermore, the effect of different media conditions and
the  drug loading on the CHX release was assessed.
Methods: Resin specimens were prepared from a hard denture reline material based on
poly(ethylmethacrylate) (PEMA) and isobutylmethacrylate (IBMA) containing 2.5, 5.0, 7.5 and
10  wt% of CHX. The CHX-loaded resins were incubated in water and artiﬁcial saliva (at pH
7)  for up to 28 days at 37 ◦C. Chlorhexidine content was determined by UV-spectroscopy
(255  nm).
Results: CHX release was inﬂuenced by media composition and drug loading. CHX demon-
strated a similar release proﬁle in the two media, however the water showed the higher
amount of release in comparison with the inorganic mimetic saliva. CHX release increased
proportionally to the concentration of the CHX added, in a linear trend line. Moreover, a
high  percentage of CHX was not release up to 28 days.
Conclusions: Despite the limitations of the present investigation, results from the present
study highlight the need of evaluating drug release not only in water but also in saliva. Strate-
gies  that increase the complete release of drug from the material should be investigated in
order to prevent the development of multiresistant strains.©  2016 Sociedade Portuguesa de Estomatologia e Medicina Denta´ria. Published by
Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail address: asimao@ff.ul.pt (A.F. Bettencourt).
ttp://dx.doi.org/10.1016/j.rpemd.2016.04.001
646-2890/© 2016 Sociedade Portuguesa de Estomatologia e Medicina Denta´ria. Published by Elsevier Espan˜a, S.L.U. This is an open access
rticle  under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Veiculac¸ão  de  clorhexidina  em  resinas  acrílicas  de  rebasamento:
avaliac¸ão  da  libertac¸ão  do  fármaco
Palavras chave:
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Estomatite protética
r  e  s  u  m  o
Objetivos: A veiculac¸ão localizada de fármacos em biomateriais dentários é uma estratégia
que tem vindo a ser considerada para tratamento de infec¸ões designadamente por Candida
albicans. Neste contexto, surgiu o interesse em avaliar a incorporac¸ão do fármaco clorhexi-
dina  (CHX) em resinas acrílicas de rebasamento. O principal objetivo deste estudo foi avaliar
o  perﬁl de libertac¸ão da CHX a partir de diferentes formulac¸ões de uma  resina acrílica de
rebasamento direto, Kooliner (K), constituídas por diferentes percentagens de fármaco e em
diferentes meios de libertac¸ão.
Métodos: Foram preparados espécimes da resina K com 2,5; 5,0; 7,5 e 10% (m/m) de CHX.
Os  ensaios de libertac¸ão foram realizados em água e saliva artiﬁcial (pH = 7). A concentrac¸ão
de  CHX no meio foi quantiﬁcada através de Espectroscopia UV-Visível (255 nm).
Resultados: Os ensaios realizados permitiram concluir que a libertac¸ão é inﬂuenciada pela
composic¸ão  do meio e pela percentagem em massa de CHX incorporada nos espécimes.
A  maior concentrac¸ão de CHX foi veriﬁcada na água e maiores percentagens de CHX con-
tribuíram para a libertac¸ão de maiores quantidades de fármaco. Veriﬁcou-se ainda que
apenas uma pequena percentagem de CHX inicialmente incorporada no material foi lib-
ertada para os meios.
Conclusão: Os resultados obtidos neste estudo vêm reforc¸ar a ideia de que é necessária a
realizac¸ão  dos ensaios não só em água mas também em meios que mimetizem a saliva.
Estratégias que permitam a libertac¸ão completa de CHX a partir de resinas acrílicas devem
ser  investigadas para diminuir a probabilidade de desenvolvimento de estirpes multirre-
sistentes.
©  2016 Sociedade Portuguesa de Estomatologia e Medicina Denta´ria. Publicado por
Elsevier Espan˜a, S.L.U. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://Introduction
Despite dramatic improvements in tooth retention around
the world, a substantial proportion of older adults have
lost natural teeth and many  wear removable partial or
complete dentures.1 The Candida-associated denture sto-
matitis is a common condition among people who wear
complete dentures, characterized by generalized inﬂamma-
tion of the palatal mucosa covered by the denture.2,3 It
is a harmless form of oral candidiasis and it is associ-
ated with a quantitative increase of yeasts on the mucosa
and the denture’s ﬁt surface.4 Although denture stomatitis
appears to be caused by a multiplicity of predisposing fac-
tors, Candida albicans has been claimed to be the principal
pathogen.4,5
Materials for prostheses, such as acrylic resins, represent
a perfect support for bioﬁlm formation. C. albicans has been
found on both hard and soft denture base acrylic resins in vitro
and in vivo.4 The chemical and physical characteristics of the
surface of these materials support bioﬁlm formation through
reversible and then irreversible adhesion to the surface.6
Microorganisms in the bioﬁlm can reduce metabolic activities,
form extracellular polymer matrix to defend against harm-
ful environmental physical and chemical factors, evade host
immunological surveillance and hinder the diffusion and per-
meation of antibiotics.7
A number of antimicrobial agents are available for the
management of fungal infections; however, the choice ofcreativecommons.org/licenses/by-nc-nd/4.0/).
antifungals suitable for the treatment of oral candidosis is
limited.8 Among those, chlorhexidine (CHX) has been used
as an adjunctive therapeutic option for topical application
due to its broad-spectrum antimicrobial activity, including C.
albicans.5,8 Furthermore, in comparison to another common
prescribed antifungal drug as ﬂuconazole, CHX has shown
to develop less resistant strains. In fact, despite the good
short-term ﬂuconazole efﬁciency in the treatment of Denture
Related Stomatitis (DRS) the ﬂuconazole generalized prescrip-
tion should be avoided to reduce the emergence of resistant
strains of C. albicans and the increasing episodes of DRS
recurrences.9
The mode of action of CHX on Candida spp. is still unclear
but it has been suggested that the mechanism for fungi is very
similar to bacteria.8,10 CHX is a positively-charged molecule
that binds to the negatively-charged sites on the candidal cell
wall; it destabilizes the cell wall and interferes with osmo-
sis. The fungus uptakes CHX in a short amount of time and
impairs the integrity of the cell wall and the plasma membrane
entering the cytoplasm resulting in leakage of cell contents
and cell death.10
There are many  oral delivery formulations for CHX. It is
used primarily as 0.2% mouthwash with a topical mode of
action. However, in this case most of the agent is removed
from the oral cavity during the ﬁrst hour due to the diluent
effect of saliva and the cleansing effect of the oral muscula-
ture, possibly reducing its therapeutic efﬁcacy.5 Alternatively,
CHX-impregnated acrylic-based drug delivery systems have
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een suggested for treatment of DRS due to the controlled
elease of the drug in the oral cavity.4,5,8,11–14
Although showing promising results most of these stud-
es evaluate CHX release from the acrylic resin devices just
n water. However, in order to simulate the denture-mucosa
nterface it is important to study the CHX release in a media
olution more  similar to the organic saliva.15 With this in mind
 study was designed aiming to compare the CHX release from
ne acrylic reline resin loaded with different drug amounts
2.5, 5.0, 7.5 and 10%, w/w) in water and in artiﬁcial saliva.
The acrylic resin selected for this purpose was a hard chair-
ide reline resin. This material is supplied as a power and
iquid, the power consisting of poly(ethylmethacrylate) and
he liquid containing isobutylmethacrylate. A direct relining
ystem is not only simple and practical to perform but also
ime- and cost-effective. Advantages of the hard chairside
eline resins include ease of manipulation and low exothermic
eat of reaction.16–18
The tested hypotheses of the study were: ﬁrst, increasing
rug resin loading increases CHX liberation; and second, drug
elease is inﬂuenced by media composition.
aterials  and  methods
ne direct reline resin, Kooliner (K) (GC America Inc,
lsip, IL, USA) was used and represents a pre-polymerized
oly(ethylmethacrylate) (PEMA) based material which has
sobutylmethacrylate (IBMA) as the monomer. The mixing
atio and the conditions for processing and polymerization
ere manipulated according to the manufacturer’s instruc-
ions. These were 2.5 g/1.79 mL  polymer powder/monomer
iquid (ratio for mixing).
Fifteen specimens (10 × 2.5 mm)  of K material were pre-
ared from cylinder shaped stainless steel molds.19 On
he experimental specimens, chlorhexidine diacetate mono-
ydrate (Panreac Applichem, Darmstadt, Germany) was
ncorporated and mixed using a mortar and pestle for homog-
nization. Five groups (n = 3) of samples of K were prepared: a
ontrol group (without CHX) and 4 experimental groups with
ifferent concentrations of CHX (2.5, 5.0, 7.5 and 10%, w/w)
owder.
For each specimen preparation, the stainless steel mold
as placed on a polyester sheet. The material was prepared
nd placed into the mold. A new polyester sheet was pos-
tioned on top of the mold and the set was maintained under
ompression into an incubator at 37 ± 2 ◦C (Memmert incuba-
or) during polymerization, in order to simulate the intraoral
olymerization of direct reline resin.
After polymerization, the samples were removed from the
olds and the edges of each sample were polished with a 600-
rit silicon carbide paper (Carbimet Paper Discs, Buehler Ltd.,
ake Bluff, IL) in order to remove any irregularities.
A standard stock solution of 1000 g/mL was prepared by
issolving 10 mg  of CHX in 10.0 mL  of deionized water. The
olution was then kept out of the light, at room temperature.The releasing solutions used in this study were: deionized
ater and artiﬁcial saliva at pH = 7. The artiﬁcial saliva used
n the present study was prepared according to the formula,
ith the following qualitative composition: phosphate buffer a x i l o f a c . 2 0 1 6;5  7(3):125–131 127
pH = 7.0 (anhydride disodium phosphate, monosodium phos-
phate anhydride and deionized water), xanthan gum, calcium
chloride dihydrat, sodium chloride, potassium chloride and
propylene glycol.20,21
The determination of CHX was conducted using
polystyrene ﬂat-bottom microplate wells (96-well microplates)
in a microplate reader (FLUOstar Omega  – BMG  LABTECH).
Using an Ultraviolet-Visible Absorbance Spectra detection
mode, three absorbance peaks were detected for the standard
stock solution of CHX at 230 nm,  250 nm and 255 nm.  The
wavelength used in this study was 255 nm that corresponds
to the literature mentioned wavelength.22–24
The measurements were performed at room temperature
(25 ◦C). The experiments were run with repeat series using
graded dilution series of CHX from 0.06 to 1000 g/mL. Then,
200 or 300 L of a standard stock solution with 0, 0.06, 0.12,
0.24, 0.49, 0.98, 1.95, 3.91, 7.81, 15.62, 31.25 and 62.5 g/mL of
CHX was applied into the wells. Two calibration curves were
constructed for both media solution. As the capability of the
method to discriminate small differences in concentration of
CHX (sensitivity) was higher to a volume of 300 L, this was
the selected value for further analysis (after the optimization
step). The calibration curves were repeated in each new mea-
surement of CHX.
Three K specimens without CHX (control group) and three
K specimens with CHX 2.5, 5.0, 7.5 and 10% (w/w) (experimen-
tal groups) were placed separately in a graduated Falcon tube
and then covered with deionized water and artiﬁcial saliva at
pH = 7 with a ratio of 1 g/5 mL.
The 15 tubes which accommodated the samples were left
into an incubator (Memmert) at 37 ◦C, with continuous gentle
shaking (300 rpm). During appropriate time intervals of 2, 4, 7,
26, 50, 75, 171, 339, 507 and 672 h (28 days), aliquots of 300 L
were collected from each tube. The 300 L of media solution in
the 15 containers was renewed at each test interval, in order
to simulate the clinical situation regarding the dilution of the
thin salivary ﬁlm at the denture-mucosa interface. All the col-
lected samples were analyzed for CHX content as previously
described.
One-way analysis of variance (ANOVA) with a post hoc
Tukey’s test was applied to the results for the cumulative con-
centration and maximum cumulative release of CHX. The level
of statistical difference was deﬁned as p < 0.05. Data were sta-
tistically analyzed using GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA, USA).
Results
Linear relationship between absorbance peak areas at 255 nm
via a microplate reader UV-Visible Spectrophotometer and
the CHX concentrations was established for each release
media (Fig. 1). The absorbance peak areas of the samples at
255 nm were converted to the CHX released concentrations by
the respective linear relationships.22 The analytical method
showed good linearity in the two evaluated media.The release of CHX to the media (water or saliva) was
properly measured; it increased proportionally to the con-
centration of the added CHX, in a linear trend line (Fig. 2).
Considering the same media release composition, there is
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Fig. 1 – Linear relationship between absorbance peak areas and the CHX concentrations for each release solution;
(a) deionized water; (b) saliva at pH 7.
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s of Fig. 2 – Total amount of CHX release after 28 day
an effect of drug loading on drug release. In both media,
the release concentrations are signiﬁcantly different (p < 0.05),
except for 5.0 vs.  7.5% drug loading.
Figs. 3 and 4 show the representative release proﬁles of CHX
in both media. CHX demonstrated a similar release proﬁle in
the water and saliva. In all studies CHX release stops after an
initial burst phase (Figs. 5 and 6).
Fig. 7 shows the maximum cumulative release (% w/w), as
function of drug loading (theoretical values: 2.5%, 5.0%, 7.5%
and 10%) in both media. The higher amount of CHX release
was observed in water and the specimens group of 10% led
to a higher drug release. However, the maximum cumulative
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Fig. 3 – Release proﬁle of CHX in deionized water up to
28 days (672 h).storage in: (a) deionized water; (b) saliva at pH 7.
release is only 1.87 ± 0.46%, meaning that only a small amount
of initial loaded CHX is liberated to the media.
Fig. 8 shows that the CHX released concentrations are effec-
tive against Candida albicans, even with a lower loading of CHX
(2.5%), in both release solutions.
Discussion
The effect of drug loading and release media composition on
drug liberation from methacrylate systems was investigated
in K cylinder specimens with different loading concentrations
of CHX.
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Fig. 4 – Release proﬁle of CHX in saliva at pH 7 up to
28 days (672 h).
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30The release of CHX increased proportionally to the con-
entration of the loaded drug in the polymer matrix in water
nd saliva, as shown in Fig. 2. This fact is in agreement with
revious studies in which the CHX was incorporated to hard
EMA resin and drug release was evaluated in water.14,25,26
nce the materials are immersed in the release media, the
iquid diffuses into the polymeric matrix and dissolve the
rug upon contact. The drug particles, when dissolved, leave
ehind pores and channels in the polymer structure. The drug
olecules can then diffuse out through the interconnecting
ores. As the drug loading increases, the pores created by
he occupied drug molecules would be larger and/or greater
n number and the release of the drug would be in high
2.5
2.0
1.5
1.0
CH
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ig. 7 – Maximum cumulative release of CHX in deionized
ater and saliva at pH 7 (t = 28 days). * Means a statistical
igniﬁcant difference (p < 0.05).(MIC) values (t = 24 h and 48 h) for Candida albicans .
amount.25–27 Release proﬁles in both media showed that CHX
release stops after an initial burst (Figs. 3–6). Studies with
other acrylic resins in water showed different results.4,5,13
In the present study, the amount of CHX released in water
was markedly lower than previously reported results with a
poly-ethyl methacrylate and tetrahydro-furfuryl methacrylate
(PEM/THFM) drug-release device.13 Moreover, a burst release
was also described for an auto-polymerized poly(methyl
methacrylate) (PMMA) based resin but CHX  leach steadily out
of the resin into water and sustained drug release continued
throughout the 28 day-test period.4,5 These dissimilar conclu-
sions in comparison with our investigation may be due to the
differences in the experimental protocol, namely, the com-
position of the tested acrylic resin and type of specimens.
Concerning acrylic resin composition, there are many  vari-
ables inﬂuencing polymer matrix structure after setting, as
the type of monomer, polymer molecular weight, polymeriza-
tion reaction, among others. These differences will directly
affect material porosity and consequently drug release.19,28
The dimensions and surface area of the tested specimens may
also affect the results as release is inﬂuenced by surface area.
In the mentioned studies,4,5,13 discs were used whereas in our
study the tested model was a cylinder. A proportionally larger
surface area of the disks exposes more  drug to the soaking
solution and thus may enhance its release.
A direct comparison between the amount of CHX release
in water and saliva show that it is signiﬁcantly inﬂuenced
by media composition (Fig. 7). In fact, for all the differ-
ent tested drug-loaded percentages, CHX release was always
lower in saliva. A similar conclusion was observed in a
study of CHX embedded into methyl (methacrylate) and 2-
hydroxyethyl(methacrylate) copolymer device.29 It was shown
that the release rates in an inorganic saliva were signiﬁcantly
lower than those observed from similar devices in water. It
was hypothesized that the chloride in the saliva media had
diffused into the core of the device, and converted the acetate
salt of chlorhexidine (solubility ≈ 23 g/L at 37 ◦C) to the less sol-
uble chloride salt (solubility ≈ 1 g/L at 37 ◦C). The lower amount
of release of CHX in saliva observed in this study is consis-
tent with the assumption that a dramatic reduction in drug
release rates are to be expected in human saliva by the same
mechanism.
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Finally, our results show that even for the lowest loaded
CHX concentration (2.5%), drug release concentrations were
always higher than the minimum inhibitory concentration of
C. albicans reported in the literature30 as illustrated in Fig. 8.
However, a lot of drug remains in the device (the highest per-
centage was around 2% in relation to the total amount of
loaded drug) as seen in Fig. 7. This is an overlooked aspect in
the published papers and it is highly important when consid-
ering a candidate material for local drug delivery. In fact, a total
release of CHX from the device is essential as the presence of
the drug after a long-term implantation period will contribute
to induce and/or select resistant strains.19,31
Future investigations should be carried out aiming to
develop systems that allow the total drug release. Inert poros-
ity enhancers as lactose that has been successfully tested for
acrylic bone cements could be a valuable strategy to be evalu-
ated in forthcoming work.19,32
Conclusions
In the present study the effect of drug loading and media com-
position on CHX release from a hard chairside reline resin
was evaluated. Results showed that increasing drug loading
enhances the release of CHX in water as well as in an artiﬁcial
saliva. Also, drug release was always lower in a more  com-
plex media as inorganic artiﬁcial saliva in comparison with
water. Data of the present investigation suggests that release
behavior of an antifungal drug, CHX, contained within a drug-
release device is inﬂuenced by polymer composition, tested
specimen and release media. Standardization of experimen-
tal protocols must be a priority in order to compare the results
among different studies. Furthermore, as a high percentage of
CHX was not release up to 28 days, other strategies should be
considered for the development of local drug acrylic devices,
for example, including release enhancers in the material to
allow the total drug release in a measurable length of time
and avoid the development of multiresistant Candida strains.
Ethical  disclosures
Protection of human and animal subjects. The authors
declare that no experiments were performed on humans or
animals for this study.
Conﬁdentiality of data. The authors declare that no patient
data appear in this article.
Right to privacy and informed consent. The authors declare
that no patient data appear in this article.
Funding
Fundac¸ão para a Ciência e a Tecnologia (FCT), Portugal: project
iMed.ULisboa (UID/DTP/04138/2013).Conﬂicts  of  interest
The authors have no conﬂicts of interest to declare.
1 m a x i l o f a c . 2 0 1 6;5  7(3):125–131
Acknowledgements
The authors would also like to express their thanks to Prof.
António Almeida, MsC Rosana Pinto, MsC  Joana Marto and PhD
Ana Matos of the Faculty of Pharmacy, University of Lisbon.
 e  f  e  r  e  n  c  e  s
1. Jones J, Orner M, Spiro A, Kressin N. Tooth loss and dentures:
patients’ perspectives. Int Dent J. 2003;53:327–34.
2. Ruby J, Barbeau J. The buccale puzzle: the symbiotic nature of
endogenous infections of the oral cavity. Can J Infect Dis.
2002;13:34–41.
3. Coco B, Bagg J, Cross L, Jose A, Cross J, Ramage G. Mixed
Candida albicans and Candida glabrata populations associated
with the pathogenesis of denture stomatitis. Oral Microbiol
Immunol. 2008;23:377–83.
4. Amin W,  Al-Ali M, Salim N, Al-Tarawneh S. A new form of
intraoral delivery of antifungal drugs for the treatment of
denture-induced oral candidosis. Eur J Dent. 2009;3:257–66.
5. Ryalat S, Darwish R, Amin W.  New form of administering
chlorhexidine for treatment of denture-induced stomatitis.
Ther Clin Risk Manag. 2011;7:219–25.
6. Marra J, Paleari A, Rodriguez L, Leite A, Pero A, Compagnoni
M. Effect of an acrylic resin combined with an antimicrobial
polymer on bioﬁlm formation. J Appl Oral Sci. 2012;20:
643–8.
7. He S, Zhou P, Wang L, Xiong X, Zhang Y, Deng Y, et al.
Antibiotic-decorated titanium with enhanced antibacterial
activity through adhesive polydopamine for dental/bone
implant. J R Soc Interface. 2014;11:20140169.
8. Salim N, Moore C, Silikas N, Satterthwaite J, Rautemaa R.
Chlorhexidine is a highly effective topical broad-spectrum
agent against Candida spp. Int J Antimicrob Agents.
2013;41:65–9.
9. Figueiral MH, Fonseca P, Lopes MM, Pinto E, Pereira-Leite T,
Sampaio-Maia B. Effect of denture-related stomatitis
ﬂuconazole treatment on oral candida albicans susceptibility
proﬁle and genotypic variability. Open Dent J. 2015;30:46–51.
0. Mcdonnell G, Russell D. Antiseptics and disinfectants: activity,
action, and resistance. Clin Microbiol Rev. 1999;12:147–79.
1. Patel M, Cruchley A, Coleman D, Swai H, Braden M, Williams
D.  A polymeric system for the intra-oral delivery of an
anti-fungal agent. Biomaterials. 2001;22:2319–24.
2. Salim N, Moore C, Silikas N, Satterthwaite J, Rautemaa R.
Fungicidal amounts of antifungals are released from
impregnated denture lining material for up to 28 days. J Dent.
2012;40:506–12.
3. Hiraishi N, Yiu CK, King NM, Tay FR, Pashley DH.
Chlorhexidine release and water sorption characteristics of
chlorhexidine-incorporated hydrophobic/hydrophilic resins.
Dent Mater. 2008;24:1391–9.
4. Bertolini M, Portela M, Curvelo J, Soares R, Lourenc¸o E, Telles
D. Resins based denture soft lining materials modiﬁed by
chlorhexidine salt incorporation: an in vitro analysis of
antifungal activity, drug release and hardness. Dent Mater.
2014;30:793–8.
5. Malakhov A, Wen J, Zhang BX, Wang H, Geng H, Chen XD,
et al. Rechargeable anticandidal denture material with
sustained release in saliva. Oral Dis. 2016;(February),
http://dx.doi.org/10.1111/odi.12456.6. Azevedo A, Machado A, Vergani C, Giampaolo E, Pavarina A,
Magnani R. Effect of disinfectants on the hardness and
roughness of reline acrylic resins. J Prosthodont.
2006;15:235–42.
 i r m
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3r e v p o r t e s t o m a t o l m e d d e n t c
7. Machado A, Breeding L, Vergani C, Da Cruz Perez L. Hardness
and  surface roughness of reline and denture base acrylic
resins after repeated disinfection procedures. J Prosthet Dent.
2009;102:115–22.
8. Neves M. Insights on the biodegradation of acrylic reline
resins. Faculdade de Medicina Dentária, Universidade de
Lisboa; 2012.
9. Matos A, Gonc¸alves L, Rijo P, Vaz M, Almeida A, Bettencourt A.
A  novel modiﬁed acrylic bone cement matrix. A step forward
on antibiotic delivery against multiresistant bacteria
responsible for prosthetic joint infections. Mater Sci Eng C
Mater Biol Appl. 2014;38:218–26.
0. Preetha A, Banerjee R. Comparison of artiﬁcial saliva
substitutes. Trends Biomater Artif Organs. 2005;18:
178–86.
1. Farmacopeia Portuguesa VIII. Comissão da Farmacopeia
Portuguesa. Instituto Nacional da Farmácia e do
Medicamento; 2005.
2. Shen C, Zhang N, Anusavice K. Fluoride and chlorhexidine
release from ﬁlled resins. J Dent Res. 2010;89:1002–6.
3. Zeng P, Zhang G, Rao A, Bowles W, Wiedmann T.
Concentration dependent aggregation properties of
chlorhexidine salts. Int J Pharm. 2009;367:73–8.
4. Nicolay A. Rapid HPLC method for determination of
parachloroaniline in chlorhexidine antiseptic agent in
mouthrinses, ophthalmic and skin solution. Am J Anal Chem.
2011;2:422–8.
5. Li J, Barrow D, Howell H, Kalachandra S. In vitro drug release
study of methacrylate polymer blend system: Effect of
polymer blend composition, drug loading and solubilizing
surfactants on drug release. J Mater Sci Mater Med.
2010;21:583–8.
3 a x i l o f a c . 2 0 1 6;5  7(3):125–131 131
6. Tallury P, Airrabeelli R, Li J, Paquette D, Kalachandra S. Release
of  antimicrobial and antiviral drugs from methacrylate
copolymer system: Effect of copolymer molecular weight and
drug loading on drug release. Dent Mater. 2008;24:274–80.
7. Lin DM, Kalachandra S, Valiyaparambil J, Offenbacher S. A
polymeric device for delivery of anti-microbial and
anti-fungal drugs in the oral environment: Effect of
temperature and medium on the rate of drug release. Dent
Mater. 2003;19:589–96.
8. Kasina SP, Ajaz T, Attili S, Surapaneni H, Cherukuri M, Srinath
HP. To evaluate and compare the porosities in the acrylic
mandibular denture bases processed by two  different
polymerization techniques, using two different brands of
commercially available denture base resins – an in vitro
study. J Int Oral Health. 2014;6:72–7.
9. Nerurkar M, Zentner G, Rytting J. Effect of chloride on the
release of chlorhexidine salts from methylmethacrylate:
2-hydroxyethyl methacrylate copolymer reservoir devices. J
Control Release. 1995;33:357–63.
0. Salim N, Silikas N, Satterthwaite J, Moore C, Ramage G,
Rautemaa R. Chlorhexidine-impregnated PEM/THFM polymer
exhibits superior activity to ﬂuconazole-impregnated
polymer against Candida albicans bioﬁlm formation. Int J
Antimicrob Agents. 2013;41:193–6.
1. Neut D, van de Belt H, van Horn JR, van der Mei  HC, Busscher
HJ.  Residual gentamicin-release from antibiotic-loaded
polymethylmethacrylate beads after 5 years of implantation.
Biomaterials. 2003;24:1829–31.2. Matos AC, Ribeiro IA, Guedes RC, Pinto R, Vaz MA,  Gonc¸alves
LM, et al. Key-properties outlook of a levoﬂoxacin-loaded
acrylic bone cement with improved antibiotic delivery. Int J
Pharm. 2015;485:317–28.
